secwatch.observer — SEC 8-K summary
======================================

Issuer:     Inhibitor Therapeutics, Inc. (INTI)
CIK:        0001042418
Form:       8-K
Filed at:   2025-10-27T23:59:59+00:00
Accession:  0001493152-25-019381
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 1.01, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Inhibitor Therapeutics enters Frameshift consulting pact for Gorlin syndrome; 18M warrants possible
--------------------------------------------------------------------------------

- Entered Master Services Agreement with Frameshift Management for biostatistics, regulatory, and business development support for itraconazole program in Gorlin's syndrome.
- Performance-based compensation includes up to 18 million unvested 4-year warrants, vesting upon milestones such as FDA approval or sale of program.
- First SOW involves re-analysis of HP2001 clinical study data and preparing FDA meeting request (Type B/C/D).
- Board adopted 2025 Equity Incentive Plan reserving 20 million shares; subject to shareholder approval within 12 months.
- Consulting agreement continues indefinitely; each project governed by separate SOWs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1042418/000149315225019381/0001493152-25-019381-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1042418/000149315225019381/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-019381

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer